Drug Profile
BARI 1453
Latest Information Update: 15 Jul 2008
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 31 May 2004 This compound is still in active development
- 02 Jul 2002 Phase-II clinical trials in Hypercholesterolaemia (unspecified route)